Effexor Follow-On Will Launch One Year Before XR Patent Expires, Wyeth Says

Advantages of DVS-233 over venlafaxine XR include improved safety profile and no dose titration requirement, Wyeth says. DVS-233 is also in Phase III studies for the treatment of vasomotor symptoms associated with menopause. Wyeth expects to file for approval in 2006.